Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities researchers at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Acrivon Therapeutics in a report released on Wednesday, April 30th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($1.95) per share for the year, up from their previous estimate of ($2.55). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.09.

A number of other research analysts have also issued reports on ACRV. HC Wainwright dropped their target price on Acrivon Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. KeyCorp began coverage on shares of Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Acrivon Therapeutics currently has an average rating of “Buy” and an average price target of $21.80.

Acrivon Therapeutics Stock Up 6.0 %

NASDAQ ACRV opened at $1.41 on Friday. The business’s 50-day moving average price is $3.20 and its 200 day moving average price is $5.45. The firm has a market cap of $44.21 million, a P/E ratio of -0.52 and a beta of 1.77. Acrivon Therapeutics has a 52-week low of $1.30 and a 52-week high of $10.29.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ACRV. Acorn Capital Advisors LLC acquired a new stake in Acrivon Therapeutics in the fourth quarter valued at $2,440,000. State Street Corp increased its holdings in Acrivon Therapeutics by 26.4% during the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after acquiring an additional 47,233 shares in the last quarter. JPMorgan Chase & Co. raised its position in Acrivon Therapeutics by 548.3% during the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock worth $238,000 after acquiring an additional 28,748 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Acrivon Therapeutics by 29.7% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock valued at $619,000 after purchasing an additional 23,535 shares in the last quarter. Finally, Corton Capital Inc. acquired a new stake in shares of Acrivon Therapeutics in the fourth quarter valued at approximately $73,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

Insider Buying and Selling

In other Acrivon Therapeutics news, major shareholder Perceptive Advisors Llc sold 215,283 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $1.56, for a total value of $335,841.48. Following the completion of the transaction, the insider now directly owns 4,090,906 shares of the company’s stock, valued at approximately $6,381,813.36. This trade represents a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 1,707,833 shares of company stock valued at $3,009,858 over the last quarter. Company insiders own 8.50% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.